



PRODUCT: **Dupixent® (dupilumab)**

COMPANY: Regeneron and Sanofi

THERAPEUTIC AREA & INDICATION:

Single dose pre-filled pen technology to treat adults and adolescents with atopic dermatitis (eczema), asthma and rhinosinusitis with nasal polyposis

ABOUT THE PRODUCT

Dupixent is a biologic currently approved in the U.S., Europe, Japan and other countries around the world for use in specific patients with moderate-to-severe atopic dermatitis as well as certain patients with asthma or chronic rhinosinusitis with nasal polyposis (CRSwNP) in different age populations. Excessive type 2 inflammation is an over-active immune response that can contribute to diseases like atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis. For decades, scientists have evaluated ways to inhibit the biologic pathways that underlie these types of diseases. Dupixent® (dupilumab) is the first fully human monoclonal antibody that inhibits the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two proteins that play a major role in type 2 inflammation. Regeneron and Sanofi are also studying dupilumab in a broad range of clinical development programs for diseases driven by allergic and other type 2 inflammation.